Giandomenico Roviello, Federico Paolieri, Martina Catalano, Luca Galli, Laura Doni, Federico Peschiera, Alessandro Pili, Michele Sisani, Bloise Francesco
{"title":"高危肾细胞癌的辅助免疫治疗：适应症、局限性和前景。GIOTTO泌尿肿瘤小组的共识声明。","authors":"Giandomenico Roviello, Federico Paolieri, Martina Catalano, Luca Galli, Laura Doni, Federico Peschiera, Alessandro Pili, Michele Sisani, Bloise Francesco","doi":"10.1016/j.critrevonc.2025.104978","DOIUrl":null,"url":null,"abstract":"<p><p>Renal cell carcinoma (RCC) is often diagnosed at a localized stage and treated with surgery. However, up to 40% of patients may experience recurrence despite complete resection. The introduction of immune checkpoint inhibitors, particularly pembrolizumab, has changed the adjuvant treatment landscape. The Tuscan Interdisciplinary Uro-Oncological Group (GIOTTO) provides practical guidance on patient selection and clinical use of adjuvant pembrolizumab in RCC.</p>","PeriodicalId":93958,"journal":{"name":"Critical reviews in oncology/hematology","volume":" ","pages":"104978"},"PeriodicalIF":5.6000,"publicationDate":"2025-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Adjuvant Immunotherapy in High-Risk Renal Cell Carcinoma: Indications, Limitations, and Perspectives. A Consensus Statement from the GIOTTO Uro-Oncology Group.\",\"authors\":\"Giandomenico Roviello, Federico Paolieri, Martina Catalano, Luca Galli, Laura Doni, Federico Peschiera, Alessandro Pili, Michele Sisani, Bloise Francesco\",\"doi\":\"10.1016/j.critrevonc.2025.104978\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Renal cell carcinoma (RCC) is often diagnosed at a localized stage and treated with surgery. However, up to 40% of patients may experience recurrence despite complete resection. The introduction of immune checkpoint inhibitors, particularly pembrolizumab, has changed the adjuvant treatment landscape. The Tuscan Interdisciplinary Uro-Oncological Group (GIOTTO) provides practical guidance on patient selection and clinical use of adjuvant pembrolizumab in RCC.</p>\",\"PeriodicalId\":93958,\"journal\":{\"name\":\"Critical reviews in oncology/hematology\",\"volume\":\" \",\"pages\":\"104978\"},\"PeriodicalIF\":5.6000,\"publicationDate\":\"2025-10-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Critical reviews in oncology/hematology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.critrevonc.2025.104978\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Critical reviews in oncology/hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.critrevonc.2025.104978","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Adjuvant Immunotherapy in High-Risk Renal Cell Carcinoma: Indications, Limitations, and Perspectives. A Consensus Statement from the GIOTTO Uro-Oncology Group.
Renal cell carcinoma (RCC) is often diagnosed at a localized stage and treated with surgery. However, up to 40% of patients may experience recurrence despite complete resection. The introduction of immune checkpoint inhibitors, particularly pembrolizumab, has changed the adjuvant treatment landscape. The Tuscan Interdisciplinary Uro-Oncological Group (GIOTTO) provides practical guidance on patient selection and clinical use of adjuvant pembrolizumab in RCC.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
